Recombinant Vaccines Market: Size, Share, Growth, Analysis, Key Players, Revenue, Growth | Valuates Reports

Recombinant Vaccines Market Size
According to new survey, global Recombinant Vaccines market is projected to reach US$ 17170 million in 2029, increasing from US$ 8152 million in 2022, with the CAGR of 11.0% during the period of 2023 to 2029.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-27L6724/Global_Recombinant_Vaccines_Market_Insights_and_Forecast_to_2028

Recombinant Vaccines Market
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Vaccines market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Get regional report
https://reports.valuates.com/request/regional/QYRE-Auto-27L6724/Global_Recombinant_Vaccines_Market_Insights_and_Forecast_to_2028

Segment by Type
• Subunit Recombinant Vaccines
• Attenuated Recombinant Vaccines
• Vector Recombinant Vaccines

Segment by Application
• Recombinant Human Vaccines
• Animal Recombinant Vaccines

By Company
Merck & Co., Inc, Green Cross Corporation, Pfizer Inc., Bayer AG, Sanofi S A., Protein Science Corporation, GlaxoSmithKline Plc., Novartis AG, Bharat Biotech, AstraZeneca Plc., Johnson & Johnson, Emergent BioSolutions Inc, Novavax, Inc, Serum Institute of India Pvt. Ltd, Dynavax Technologies Corporation

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-27L6724/global-recombinant-vaccines

Get similar reports
1. https://reports.valuates.com/market-reports/QYRE-Auto-4Y9119/global-veterinary-vaccine-adjuvants
2. https://reports.valuates.com/market-reports/QYRE-Auto-37E406/global-pneumococcal-vaccine
3. https://reports.valuates.com/market-reports/QYRE-Auto-3I3192/global-aquaculture-vaccine

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.